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Abstract
Antisense oligodeoxynucleotides are potential therapeutic agents, but their development is still limited by both a poor
cellular uptake and a high degradation rate in biological media. The strategy that we propose to face these problems is to
 .use small synthetic carriers, around 30 nm diameter, the SupraMolecular BioVectors SMBV .
We used positively charged SMBV and settled the ionic incorporation of negatively charged oligonucleotides into these
carriers. A minimal leakage of 10% of total incorporated oligonucleotides was then measured during two months.
Both protection and uptake of oligonucleotides were then analyzed. On the one hand, we showed that the incorporation
of oligonucleotides into the selected SMBV allows to significantly increase, 8 times, their half-life, in cell growth medium.
On the other hand, the internalization of the SMBV, into cells, by an endosomal pathway has been characterized. The
essential point is that the SMBV uptake elicits the simultaneous oligonucleotide uptake. The oligonucleotide amount that
goes through cells within 5 h can be up to 30 times higher than for free oligonucleotides and the fraction of oligonucleotides
that is present in the cytosol is increased up to 10 fold after incorporation into the SMBV. This study demonstrates the
ability of SMBV to improve oligonucleotide cellular behaviour.
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1. Introduction
 .Antisense oligodeoxynucleotides ODN are de-
signed to inhibit gene expression in a sequence-
w xspecific manner 1 . Because of this property, they
represent useful tools to study gene function and they
w xmay be efficient therapeutic agents 2 . ODN have
been demonstrated to act as specific inhibitors of
w xgene expression in a variety of in vitro models 3
w xand of cell proliferation in vivo 4,5 . The potential
action sites of ODN are numerous on pre-mRNA or
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w xon mature mRNA 1 . They may act either by a
physical blocking or by the cleavage of the RNA
strand of RNArDNA duplexes by cellular ribo-
 .nuclease H RNase H . The usefulness of oligo-
nucleotides is limited by their polyanionic nature that
leads to non specific interactions with many extracel-
w xlular cationic molecules 6,7 and their poor diffusion
w xthrough the plasma membrane 8–10 . Other difficul-
ties that limit their efficiency are then their intra-
w xcellular trafficking 9 and the non specific binding to
w xintracellular cationic molecules 2,10 . Moreover, nu-
cleases, particularly 3X-exonucleases, induce fast ODN
degradation.
Many attempts have been performed to circumvent
these drawbacks, mainly chemical modifications of
w x w xODN 11 and the use of carrier systems 12 . Con-
cerning the former approach, the most promising
structural analogs of native phosphodiester ODN are
phosphorothioate ODN. They are resistant to cleav-
age by nucleases and do not inhibit RNase H cleav-
w xage 13 . These advantages quickly led to cellular and
w xpharmacokinetic studies 3,14,15 and to clinical tests
of these compounds as antitumoral and antiviral
w xagents 16 . However, the evidence of effects that are
not sequence-specific has moderated the enthusiasm
w xfor their therapeutic use 2,17,18 . The ODN carrier
strategy appears then as a better approach to improve
both the transport and the stability of unmodified
ODN, while conserving their target specificity. ODN
have been efficiently encapsulated into small lipo-
w xsomes as immunoliposomes 19,20 or pH-sensitive
w xliposomes 21 . It has been shown that encapsulation
allows the protection of ODN against nucleases and
increases their delivery into specific cells. Besides
these advantages, the degradation of ODN and their
low efficiency of encapsulation into many liposomes
w x22 are major drawbacks for the targeted delivery
approach. Besides, it has been proposed an interac-
tion of cholesterol conjugated ODN with natural LDL
that revealed prolonged plasma half-life from 1 to 10
. w xmin 23 and an in vitro improvement of antisense
w xefficacy 24 . Nevertheless, the obtention of LDL
 .from human plasma and the weak stability of the
encapsulated ODN remain major handicaps to their
therapeutic use. Synthetic cationic lipids such as
DOTMA or DOTAP, first used for DNA transfection,
w xare attractive ODN carriers too 25,26 . Their effi-
ciency has been proved and especially,
ODNrDOTAP complexes allow an enhancement of
ODN uptake as well as a decrease of extra- and
w xintracellular ODN degradation 26 . Nevertheless, the
cellular toxicity of these complexes limit their use for
w xin vitro experiments 12,27 or local administration
w x28 . More recently, the ODN adsorption on
polyalkylcyanoacrylate nanoparticules led to an in-
w xcreased protection against nuclease degradation 29 .
Inhibition of neoplastic growth in nude mice was
obtained with a concentration of ODN adsorbed on
nanoparticules, 100 times lower than for free ODN
w x30 . But systemic use of these carriers has not yet
been shown. In brief, considering the main current
carriers, none of them fill yet all the requirements for
w xtherapeutic use of ODN 12 .
 .The SupraMolecular BioVectors SMBV appear
then as new promising ODN carriers. They are
multi-layered particles, around 30 nm diameter, com-
posed of an internal core of cross-linked polysaccha-
rides, externally grafted with fatty acids and sur-
rounded by a lipid layer. Their synthesis can be
modulated and controlled to allow an efficient drug
w xcellular uptake and intracellular trafficking 31–34 .
SMBV have been shown to efficiently entrap drugs,
such as gentamicin and doxorubicin, with entrapment
w xyields of, respectively, 95 and 70% 33 . Moreover,
association of interleukin-2 with SMBV allows the
stabilization and an enhancement of the biological
w xactivity of the cytokine 35 . Besides the incorpora-
tion of these positively charged drugs, the SMBV
structure has been adapted to the requirements both
of the incorporation of anionic ODN into a cationic
core and of their intracellular release.
The aim of this study is to evaluate the ability of
the SMBV to be ODN carriers. We optimized the
incorporation efficiency of ODN into selected SMBV
and were allowed to show a dramatic enhancement of
both ODN protection and cellular uptake, after incor-
poration of ODN into SMBV.
2. Materials and methods
2.1. Materials
RPMI 1640 growth medium and FBS were ob-
 .tained from Gibco France and palmitoyl chloride
 .from Fluka France , cholesterol, chloroquine, de-
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oxyglucose, monensin, nonidet P-40, N-propyl-
 .gallate, sodium azide and MTT from Sigma France ,
 . w32 xEYPC from Lipoid Germany , g- P -ATP from
 .  .ICN France and Hecameg from Vegateg France .
2.2. Synthesis and labelling of ODN
We used 18 mer phosphodiester oligodeoxynu-
 .cleotides ODN with a sequence complementary to
the AUG initiation site of the chloramphenicol acetyl
 .  Xtransferase CAT mRNA 5 -AGT GAT TTT TTT
. w xCTC CAT-3’ , according to Bunnell 36 . Unlabelled
ODN and fluorescent ODN, bearing a fluorescein
moiety at the 5X-end, were synthesized and HPLC
 .purified by Genset France .
Radioactive ODN were 5X-end labelled with g-
w32 x P -ATP using a T4 polynucleotide kinase Boeh-
.ringer Mannhein, France at 378C for 1 h, purified by
exclusion column, ethanol precipitated and resus-
pended in water.
2.3. SMBV composition and ODN incorporation
SMBV were provided by Biovectors Therapeutics.
w xThey were synthesized as already described 32–34 .
Briefly, they were polysaccharides cross-linked with
 .2–3 epoxy-chloropropane epichlorydrin and cation-
ically functionnalized with glucidyl trimethyl-
 .ammonium chloride. Polysaccharide core PSC were
acylated as previously described. The acylated cores
 . 5 mg were dispersed in 1 ml of lipid solution 5 mg
 .of EYPCrcholesterol, 80r20 wrw in 50 mM
.Hecameg . The resulting mixture was then quickly
diluted with 4 ml of water under ultrasonic probe
 .Vibracell, Bioblock, France . Resulting SMBV were
finally extensively dialysed against water, at 48C,
during 48 h. SMBV were sterilized on 0.22 mm
 .filters Nalgene, France . Charge determination was
performed by titration.
For fluorescent SMBV synthesis, acylated cores
were labelled with DTAF Dichloro Triazo Amino
.Fluorescein, Molecular Probes, UK using a
 . w xDTAFracylated core ratio of 2.5% wrw 37 .
SMBV concentrations are expressed as mgrml of
PSC. All SMBV stock solutions were adjusted to 1
mgrml of PSC.
For ODN incorporation, ODN solution in water
was slowly added to PSC or SMBV suspension 1
.mgrml and kept at 458C, under magnetic stirring,
during 5 h. ODN were added, according to the tested
 .incorporation yield 2.5 to 10%, wrw . At the end of
the experiment, free and incorporated ODN were
separated by ultrafiltration on microsep 300 kDa,
.Filtron, France . Free ODN concentrations were mea-
sured in the ultra filtrate by UV spectrophotometry at
262 nm.
2.4. ODNrSMBV complex characterization
2.4.1. Stability in PBS
In order to evaluate the stability of ODN incorpo-
ration, 0.9 ml of ODNrSMBV suspension were
mixed with 0.1 ml of PBS, 10 times concentrated.
The suspension was then incubated at 378C and
ultrafiltered on microsep, in order to separate free and
incorporated ODN. Free ODN concentrations were
then measured as described above.
2.4.2. Size determination
The size of SMBV was measured with a photon
correlation laser light-scattering method using a Coul-
 .ter N4ND submicron analyser Coultronics, France .
2.5. Determination of the ODN protection against
degradation, by SMBV components
2.5.1. Degradation by phosphodiesterase
Radioactive ODN were either incorporated into
acylated cores or incorporated into SMBV 100
.mgrml ODN final concentration or associated to
lipids 5 mgrml of EYPCrcholesterol, 80r20, wrw,
diluted, sonicated and dialysed as for SMBV prepara-
.tion . Samples were then incubated, at 378C, in pres-
y3  Xence of 4P10 U of phosphodiesterase 3 -ex-
.onuclease, Boehringer-Mannheim, France , for 1 h.
The reaction was stopped by a 10 min incubation of
samples at 658C. They were then analyzed using 20%
non-denaturing PAGE. Degradation patterns were ob-
served by autoradiography.
2.5.2. Degradation in ˝arious media
Radioactive ODN, free or incorporated into SMBV
 .10% incorporation yield , were incubated at 378C,
either with RPMI 1640 medium containing 10% FBS
or with RPMI 1640 medium containing 10% heat-in-
activated FBS or with human plasma collected and
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pooled from donors of ‘Centre de Transfusion San-
guine de Toulouse’, tested HIV-negative by ELISA
.kit, Abbott, France . Final concentrations were re-
spectively 62.5 mgrml and 6.25 mgrml for SMBV
and ODN. After various incubation times, aliquots of
each sample were collected, incubated for 1 h at
658C, to stop any nuclease activity of the serum, and
stored at 48C. Samples were then analyzed as de-
scribed above and autoradiographs were quantified
by scanning, using a Kodak DCS 200 numeric cam-
era and an Optimas 4.8 image analysis software.
Mean grey values and area of non degraded ODN
were determined for each sample. Results were ex-
pressed as percentages of the sample collected at
 .initial time 100% .
2.6. Cell culture
The human adenocarcinoma breast cell line MCF-
.7 was grown routinely in RPMI 1640 growth
medium, supplemented with 10% FBS and containing
4.5 grl glucose. When specified, FBS was heat-in-
activated at 658C during 1 h. All cells were incubated
at 378C in a humidified 5% CO incubator.2
2.7. Uptake studies
2.7.1. Fluorescent SMBV uptake analyzed by flow
cytometry
2P105 MCF-7 cells were seeded in 35-mm Petri
 .culture dishes Nunc, France . 24 h later, cells were
washed once with PBS. Then 1 ml of growth medium
containing 10% heat-inactivated FBS, with or without
0.1 mM chloroquine and with or without 10 mM
sodium azide and 10 mM deoxyglucose, was added
per dish. After 1-h incubation at 48C or at 378C,
fluorescent SMBV, loaded or not with ODN, were
added at various concentrations. Cells were again
incubated at 48C or at 378C during various incubation
times, then washed twice with PBS and collected by
trypsinization. Cells were centrifuged 120=g, 5
.min, 158C washed twice with PBS and resuspended
in PBS. An aliquot of each sample was treated during
40 min at room temperature in 20 mM final concen-
tration of monensin. Cells were then analyzed by
flow cytometry, on a Facscan flow cytometer Becton
.Dickinson, France with a 488 nm laser excitation
and a 530 nm emission filter. Data was acquired on
104 viable cells and mean fluorescence values were
collected.
2.7.2. Fluorescent ODN uptake analyzed by flow
cytometry
Cells were treated and analyzed according to the
protocol described above, excepted that they were
incubated in presence of various concentrations of
either free fluorescent ODN or unlabelled SMBV
loaded with fluorescent ODN. Monensin was added
in all samples at 20 mM final concentration.
2.7.3. Confocal microscopy analysis
2P105 MCF-7 cells were grown in monolayers by
plating them on 18=18 mm2 sterile glass coverslips,
 .set in 35-mm Petri dishes Nunc, France . After 48 h,
cells were washed once with PBS and 1 ml of growth
medium containing 10% heat-inactivated FBS was
added in each dish, 1 h before SMBV treatment. The
labelled SMBV were then added at various concen-
trations. After a 3-h incubation, cells were fixed with
4% formaldehyde in PBS and permeabilized in 1%
Nonidet P-40 in PBS. Glass coverslips were then
mounted on glass slides and observed by confocal
 .analysis Microsystems LSM, Zeiss, France , with an
 .inverted microscop Axiovert 100, Zeiss, France .
For fluorescence analysis, a 488 nm laser excitation
was used, with a 510-525 nm short bandpass emis-
sion filter. Interferential contrast pictures were ob-
tained by Nomarsky analysis. In both cases, the
 . magnification was 63 immersion lens plus 2.6 elec-
.tronic zoom .
2.7.4. Radioacti˝e ODN uptake
3P105 MCF-7 cells were seeded in 60-mm Petri
culture dishes. 24 h later, cells were washed once
with PBS and 1 ml of growth medium containing
10% heat-inactivated FBS was added in each dish, 1
h before SMBV treatment. Then, at various times,
labelled ODN, free or incorporated into SMBV were
 6added 10 cpm total radioactivity with 6.25 mgrml
.of ODN and 62.5 mgrml of SMBV . The culture
medium was then removed and cells were washed
twice with PBS. The cells were collected by
 .trypsinization, centrifuged 120=g, 5 min, 158C ,
washed twice with PBS and then resuspended in
PBS. Cells were either submitted to a fractionation,
as described below, or lysed by a 1-h incubation in a
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0.5% SDS solution and radioactive ODN were
counted by liquid scintillation.
2.7.5. Cell fractionation
MCF-7 cells, treated with radioactive ODN,
trypsinized and washed as described above, were
resuspended in 0.5 ml of 10 mM TrisrHCl, pHs7.4.
All procedures were carried out at 48C. Cells were
disrupted with 40 strokes in a Dounce homogenizer
 .and centrifuged 10 000=g, 10 min . Supernatants
were centrifuged at 100 000=g for 60 min Kontron
instruments, Centrikon T-1075 ultracentrifuge, 70 Ti
.rotor, France . The supernatant and pellet obtained
refer to predominant cytosolic and microsomal frac-
tions respectively as tested by acid phosphatase ac-
.tivity . Radioactive ODN were either counted by
 .liquid scintillation or phenolrchloroform 1r1 ex-
tracted, ethanol precipitated and analyzed on a 20%
non denaturing PAGE. The degradation pattern was
visualized by autoradiography.
2.7.6. Cytotoxicity assay
 .The quantitative 3- 4,5-dimethylthiazol-2-yl -2,5
 .diphenyltetrazolium bromide MTT colorimetric as-
w xsay 38 was used to determine the toxicity of the
SMBV towards MCF-7 cells. 2500 cells were seeded
per well, in 96-well plates and grown during 24 h at
378C. Cells were then incubated, during 3 to 12 h,
with increasing concentrations of SMBV, up to 62.5
mgrml of SMBV in 200 ml final volume of growth
medium containing 10% FBS. The SMBV containing
medium was then removed and replaced with 50 ml
of a 1 mgrml MTT solution in RPMI medium,
without phenol red. The cells were incubated during
3 h at 378C, in a humidified 5% CO incubator. The2
MTT containing medium was then removed, 150 ml
of DMSO were added and cells were incubated dur-
ing 30 min in the same conditions. The blue MTT
formazan product was quantified by measuring the
optical density of the cell extract at 540 nm. For each
concentration, average viability value was calculated
from the data of 6 wells and expressed as percent-
 .ages, compared to untreated cells 100% . The IC20
values were then determined, as the SMBV concen-
trations that allow 80% of cell survival.
3. Results
3.1. Characterization of ODNrSMBV complexes
Our initial goal was to select SMBV compositions
that allow ODN efficient and stable incorporation.
The rational for ODN incorporation is based on ionic
interactions between cationically functionalized poly-
 .saccharide cores PSC and anionic ODN. Three
different PSC with similar sizes, 32.8"5 nm, and
 .with increasing charges 0.6 to 1.6 meqrg have been
tested. The results of ODN incorporation into these
 .various PSC Table 1 show high yields of ODN
 .initial incorporation 61.8 to 89.7% . Incorporation
being due to ionic interactions, it was important to
evaluate the stability of the complexes in saline
buffered solutions. Table 1 shows that a significant
leakage occurs in PBS, 30 min after incorporation 36
.to 56% . The leakage after 18 h was either increased
 .to more than 70% PSC I and II or maintained
 .around 46% PSC III . We selected thus, in a first
approach, the PSC III that exhibit a stable incorpora-
tion.
Similar experiments were performed with com-
plete SMBV, synthesized with PSC III. SMBV allow
a 100% incorporation yield, significantly different
from incorporation into PSC III alone 99.9% confi-
Table 1
Influence of polysaccharide core nature and lipid layer installation on ODN incorporation efficiency and stability in PBS
 .  .  .  .PSC I ns9 PSC II ns2 PSC III ns9 SMBV ns6
 .Charge meqrg 0.6 0.9 1.6 1.6
 .Incorporation yield % 61.8"11.5 80.2"12.4 89.7"6.0 100"4.0
 .PBS leakage % 30 min 44"16 56"12 36"10 10"6.0
18 h 73"14 78"8 46"9.0 15"10
 .Incorporation yields incorporated ODNrtotal ODN, wrw . SMBV synthesis was performed with PSC III. Data represent mean"S.E.
for 2 to 9 determinations.
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Fig. 1. Size analysis of ODNrSMBV complexes according to time. ODN incorporated into SMBV were incubated at 48C in water. At
 .different times 0 to 60 days , particle size distribution was determined on submicron nanosizer. Average particle diameters are
summarized in the insert, according to time.
dence limits by two-sample independant-groups t
.  .test . A minimal leakage in PBS 10% is observed
after a 30 min incubation and was maintained at 15%
after 18 h. We checked that this minimal leakage was
roughly constant over 2 months. All previous experi-
ments were performed with 2.5% ODNrSMBV in-
 .corporation ratios wrw . With a 10% ratio, 100%
incorporation yield and similar stability results were
obtained. In addition, we tested the effect of the
dilution factor upon the ODN leakage in PBS. The
high stability of the incorporation can be due to the
minimal dilution factor 1r1 for previous standard
.conditions , even if the ODN phosphaterPBS phos-
 y2phate ratio is low 1 to 4P10 , depending on the
.initial ODNrSMBV incorporation ratio . However,
the stable measured leakage was confirmed for dilu-
tions, up to 10-fold, of the ODNrSMBV complexes
 .in PBS data not shown . This result and the effect of
the nature of the charge of PSC on ODN incorpora-
tion indicate that the incorporation of ODN is driven
by strong ionic interactions.
Concerning the ability of the loaded SMBV to be
stored in water, the Fig. 1 summarizes the results
obtained in term of particle size analysis.
 .ODNrSMBV complexes 10% incorporation ratio ,
stored at 48C, have an initial mean size of 27"9 nm.
The solution, clear and without precipitates, exhibits
no signal above 50 nm, testifying the absence of
Fig. 2. Role of SMBV components for ODN protection against phosphodiesterase. ODN, free or incorporated, were incubated for 1 h
with phosphodiesterase and analyzed by 20% PAGE and autoradiography. ODN were free or incorporated into SMBV or incorporated
 .into acylated cores or associated to EYPCrcholesterol 80r20, wrw .
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aggregate formation. Size measurements performed
over 2 months show that the mean size of the com-
 .plexes is roughly constant Fig. 1, insert . Again,
aggregate formation was not observed during this
period of time. ODN leakage was not increased, with
a constant free ODN concentration lower than 3%,
during the 2 months.
3.2. Determination of ODN protection by SMBV
We then determine if SMBV elicit the ODN pro-
tection against nucleases. The Fig. 2 shows that free
ODN are degraded within 1 h in presence of phos-
phodiesterase while the incorporation of ODN into
SMBV allows their complete protection. To deter-
mine if this protection is the result of an inhibition of
the nuclease by one of the SMBV components, we
checked on the one hand, the degradation pattern of
ODN associated to acylated cores and on the other
hand the degradation pattern in presence of the lipid
 .  .suspension EYPCrcholesterol Fig. 2 . The results
show that the acylated cores do not protect ODN
against nuclease degradation, while the presence of
complete SMBV is necessary for ODN protection.
We then determined if, in the same way, SMBV
can protect ODN against degradation in various cell
growth media. The Fig. 3A shows that free ODN are
quickly degraded in growth medium containing FBS
 .  .minute scale , while SMBV Fig. 3B efficiently
protect ODN, whose degradation begins only after 1
h. The quantitative analysis of this experiment Fig.
.3C confirms that free ODN start to be degraded at
10 min and are completely degraded at 20 min, while
ODN incorporated into SMBV are only slightly de-
graded at 2 h. The complete degradation occurs after
6 to 8 h of incubation. The half-life of ODN shifts
 .then from 25 min to 225 min 3 h and 45 min , after
SMBV incorporation. In growth medium containing
10% heat-inactivated FBS, neither free ODN nor
incorporated ODN were degraded during 6-h incuba-
tion. When incubated in human plasma, free ODN
were only slightly degraded after 1 h and 90% de-
graded after 3 h, while ODN incorporated into SMBV
show the same degradation profile as in the growth
medium containing 10% FBS. In this latter condition,
the half-life of ODN shifts from 120 min to 225 min.
These results prove that SMBV allow a significant
protection of ODN in human plasma and in cell
Fig. 3. ODN degradation in various growth media. Radioactive
 .  .ODN, free A or incorporated into SMBV B , were incubated
for various periods of time in growth medium containing 10%
FBS, analyzed by 20% PAGE and autoradiography. Quantitation
of these results was then performed by densitometric measure-
 .ments of autoradiographs C . Degradation kinetics of free and
SMBV incorporated ODN empty and filled symbols respec-
.tively are represented. Experiments were carried out in growth
 .medium containing 10% FBS I,B , growth medium containing
 .  .10% heat-inactivated FBS ^,’ and human plasma ‘,v .
Samples were then analyzed by 20% PAGE and autoradiography.
The amount of intact ODN was determined and expressed as
percentage of the control.
growth medium, increasing markedly their life time
 .half-lives increased 2 to 8 times . In both tested
conditions, the degradation of SMBV protected ODN
is completed only after an 8-h incubation.
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3.3. SMBV cellular uptake
 .Flow cytometry analysis Fig. 4 shows that fluo-
rescent SMBV do enter into MCF-7 cells, in a dose-
dependent manner. The fluorescence level is markedly
higher than the signal of free fluorescein, used as
control. This process is saturable above 10 mgrml
 .SMBV concentration Fig. 4, insert . A constant in-
crease of the mean cell fluorescence is observed
 .during 24 h in these standard conditions 378C . It is
noteworthy that ODN incorporation, with a 10%
ratio, do not impair SMBV cellular uptake.
To analyze the mechanisms involved in SMBV
uptake and trafficking, similar experiments were car-
ried out in low energy conditions and in presence of
lysosomotropic agent. At 48C, the SMBV uptake is
weak, with fluorescence mean values lower than at
 .378C: 2 times lower after a 7-h incubation Fig. 5
and 6 times lower after a 24-h incubation data not
.shown . At 48C, a plateau is reached after 1 h. The
presence of sodium azide and deoxyglucose, that
Fig. 4. Uptake kinetics of fluorescent SMBV into MCF-7 cells,
according to SMBV concentration and ODN incorporation. Cells
were incubated with fluorescent SMBV at various concentrations:
 .  .  .1 mgrml I , 7.8 mgrml ‘ and 62.5 mgrml ^ in growth
medium containing 10% heat-inactivated FBS. Fluorescent SMBV
loaded with ODN, at a 7.8 mgrml concentration, were tested
 .v . Control free fluorescein was tested at the highest concentra-
 .tion q . The uptake of fluorescent SMBV according to their
concentration is represented in the insert at ts25 h. Mean
fluorescence intensities were obtained by flow cytometry analysis
of 104 cells.
Fig. 5. Uptake kinetics of fluorescent SMBV into MCF-7 cells,
according to the energy level and in presence of lysosomotropic
agent. Fluorescent SMBV were incubated for 8 h, at 7.8 mgrml,
in growth medium containing 10% heat-inactivated FBS at 378C
 .  .B , 48C ‘ , 378C in presence of 0.01 mM sodium azide and
 .0.01 mM deoxyglucose v and 378C in presence of 0.1 mM
 .chloroquine I . Mean fluorescence intensities were obtained by
flow cytometry analysis of 104 cells.
inhibits ATP synthesis at 378C, induces a SMBV
uptake similar to the 48C one and with a fluorescence
level 1.5 time lower than at 378C in standard condi-
tions, after a 7-h incubation. We then used chloro-
quine, that prevents the fusion of endosomes and
lysosomes, to study the intracellular fate of SMBV.
The addition of chloroquine induces an increased
fluorescence signal. Fluorescein fluorescence being
pH-dependent, SMBV that go into the acid lysosomal
 w x.compartment pHs4.7–4.8 39 lead to a low fluo-
rescence signal. In presence of chloroquine, SMBV
are blocked within the less acidic endosomal com-
 w x.partment pHs5.4 to 6, 40 and the fluorescence
signal is higher. We confirmed this hypothesis by
w xincubating aliquots of cells with monensin 41 , an
ionophore that suppresses the pH gradient inside the
cells. Such a treatment leads to the same increased
 .fluorescence signal data not shown , confirming that
SMBV are located in an intracellular acidic compart-
ment. These results indicate that the SMBV uptake is
not saturable over 24 h, is energy-dependent and that
SMBV are internalized by cells up to lysosomes.
To complete these quantitative data, we performed
fluorescence confocal microscopy studies. At 378C
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Fig. 6. Confocal analysis of MCF-7 cells treated for 5 h, with 7.8 mgrml of fluorescent SMBV, in growth medium containing 10%
 .  .  .heat-inactivated FBS. Cells were incubated either at 378C A,D or at 48C B,E or at 378C in presence of 0.1 mM chloroquine C,F .
 .  .Observation was carried out by fluorescence A,B,C or by Nomarsky analysis D,E,F . Magnifications63=2.6.
 .Fig. 6A , many small, highly fluorescent punctua-
tions are observed inside the cytoplasm, characteristic
of endocytosis, with nucleus exclusion. At 48C Fig.
.6B , these punctuations are not present and a slight
fluorescence diffuses in the cells, besides membrane
fluorescence. At last, in presence of chloroquine Fig.
.6C , fluorescent cytoplasmic punctuations are pre-
sent, with a pattern similar to that observed at 378C,
again with nucleus exclusion. These results confirm,
in turn, that the SMBV are internalized by an endoso-
mial pathway.
3.4. ODN uptake
We performed similar flow cytometry experiments
with non labelled SMBV and fluorescent ODN, to
determine if the association of ODN to SMBV is
strong enough to allow the simultaneous
ODNrSMBV uptake. As a control, free ODN were
incubated with cells and only minimal uptake was
observed, the fluorescence signal being similar to the
 .background cell fluorescence level Fig. 7 . The up-
Fig. 7. Uptake kinetics of fluorescent ODN into MCF-7 cells.
 .Free ODN at 6.25 mgrml q and ODN incorporated into 1
 .  .  .B , 7.8 v and 62.5 ’ mgrml of SMBV were incubated
with cells, in growth medium containing 10% heat-inactivated
FBS, for 24 h. The uptake of fluorescent ODN according to their
concentration is shown in the insert at ts25 h. Mean fluores-
cence intensities were obtained by flow cytometry analysis of 104
cells.
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take of fluorescent ODN mediated by the SMBV is
markedly increased, compared to free ODN.
When samples were treated with monensine, the
 .fluorescence level is increased data not shown , as
well as for SMBV uptake, testifying of the presence
of ODN, free or associated to SMBV, in acidic
compartment. All samples have, in turn, been treated
with monensine to normalize the fluorescence signals
w x .41 , Fig. 7 . As shown in the insert of Fig. 7, the
SMBV incorporated ODN uptake is a dose-dependent
process, less saturable than for SMBV uptake. Ac-
cording to the SMBV concentration 1 to 62.5
.mgrml , ODN cumulative uptake is increased 2 to 30
times compared to free ODN at 5 h. A plateau is
reached after a 5-h incubation, in contrast to the
SMBV uptake that slowly increases during the 24-h
uptake. It is noteworthy that when ODN are degraded
inside the cells, free fluorescein is poorly permeant
w xand stays mainly inside the cells 40 . The level of
fluorescence quantified in this experiment is then
representative of the cumulative amount of fluores-
 .cent ODN degraded or not that go through the cells.
The ODN uptake saturation might be explained by
the fact that, over 5 h, ODN incorporated into SMBV
are progressively degraded in presence of growth
medium and cells and do not enter cells anymore.
We used radioactive ODN to confirm the increased
uptake of ODN incorporated into SMBV, knowing
that radiolabelled nucleotides can exit cells, after
w xODN degradation 42 . Radioactivity was counted
from 3P105 MCF-7 cells, seeded in each Petri cul-
ture dish. We observed that after a 1-h incubation,
ODN incorporated into SMBV are 10 times more
concentrated in cells than free ODN 25 523
.cpmr2559 cpm . This increased uptake is 4.9 times
 .higher after a 5-h incubation 20 625 cpmr4211 cpm
and non significant after 24 h 14 630 cpmr14 290
.cpm . This agrees with a SMBV driven uptake of
ODN, followed by a release of ODN from cells, after
intracellular progressive degradation.
The subcellular location of ODN is crucial for the
biological effects. We then looked for the presence of
radioactive ODN in cell cytosol, after 1- and 5-h
 .incubations ODN uptake being maximum at 5 h .
We compared the amounts of radioactive ODN in
this fraction, with and without SMBV incorporation.
Experiments were triplicated and mean"S.E. are
expressed. We observed that ODN incorporated into
Fig. 8. Integrity of ODN in cytosolic fractions of MCF-7 cells.
 6 .  .6.25 mgrml of radioactive ODN 10 cpm , free lane 2 or
 .incorporated into 62.5 mgrml of SMBV lane 3 , were incubated
with cells for 5 h. After washings, cell fractionation, ODN were
extracted from cytosols. 1500 cpm of radioactivity were ethanol
precipitated and analyzed by a 20% PAGE and autoradiography.
A size control, i.e. intact radioactive ODN not incubated with
 .cells, was used lane 1 .
SMBV are 11.5 times more concentrated in cell
cytosols than free ODN, after a 1-h incubation 7192
."1689 cpmr626"114 cpm and 7.3 times, after a
 .5-h incubation 7907"2863 cpmr1041"237 cpm .
We looked for the presence of intact radioactive
ODN, in these cytosolic fractions after the longer
 .incubation Fig. 8 . Equal total cpm amounts have
been loaded on the gel, for both samples: cytosols of
cells treated either with free ODN or with SMBV
incorporated ODN. The proportion of intact ODN is
much higher for SMBV incorporated ODN than for
 .free ODN respectively, lanes 3 and 2 of Fig. 8 .
3.5. IC20 determinations
The cytotoxicity of SMBV on MCF-7 cells was
studied in order to determine the SMBV concentra-
tions usable for cellular study. For this, IC20, SMBV
concentrations that allow 80% of cell survival, were
determined for 3-, 6- and 12-h incubations. IC20 are
respectively 7, 2.3 and 0.8 mgrml of SMBV.
4. Discussion
The aim of this work is to demonstrate the ability
of SMBV to protect ODN against nuclease degrada-
tion and to allow their cellular uptake. We first show
that SMBV exhibiting a charge of 1.6 meqrg are
 .able to stably incorporate 10% of ODN wrw . Such
a strong association is relevant for an efficient trans-
port of ODN to cells and then for their uptake inside
cells, before ODN are released from the carrier.
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Our results show that complete SMBV, composed
of the internal acylated core and the lipid layer, allow
ODN protection. The ODN half-life is increased 8
fold in cell growth medium, guaranteing the presence
of intact ODN up to the 8 h following cell treatment.
The ODN degradation must finally be due to either
the ODN release from SMBV or to the SMBV
degradation. It is important to note that this half-life
of incorporated ODN is close to 4 h whereas efficient
ODN carriers such as DOTAP only allow to reach a
w x40-min half-life 26 . According to the manufacturer’s
w xrecommendations and publications 43,44 , actual
cationic liposomes DOTMA, GIBCO or DOTAP,
.Boehringer are often used in serum-free or at least
reduced-serum media. In the biologically relevant
case of human plasma, ODN protected by the SMBV
exhibit a half-life as long as the one observed in cell
growth medium.
Besides, any ODN carrier must exhibit both an
efficient cellular uptake and the simultaneous ODN
uptake. On the first hand, we demonstrate that SMBV
are internalized into MCF-7 cells. First, we prove the
existence of an active cellular process, independent of
a simple adsorption: the fluorescence signal observed
is decreased both at 48C and at 378C in presence of
sodium azide, compared to standard conditions at
378C. Moreover, characteristic endocytosis punctua-
tions, energy-dependent, are observed. Besides, the
fluorescence signal is altered in presence of lysoso-
 .motropic agent chloroquine or of ionophore
 .monensin , indicating that SMBV would go through
endosomes and lysosomes inside cells. Incorporation
 .of 10% ODN into SMBV WrW , that leads to
neutralization of 20% of the SMBV positive charges
by the anionic ODN, does not modify the cellular
uptake of SMBV.
On the other hand, we demonstrate that SMBV
dramatically increase the ODN uptake. When free
ODN are incubated with cells, intact ODN are not
observed inside cells, many hours after the adminis-
tration. This is only possible if ODN are driven into
cells by carriers, such as DOTAP or nanoparticles
w x26,30 . In our study, the cumulative uptake of ODN
incorporated into SMBV is plateauing after a rela-
tively short incubation time, 5 h. At this time, a
significant proportion of ODN is still present in cells.
These ODN are, at least partially, localized in the cell
acidic compartments as monensin shifts the fluores-
cence levels after fluorescent ODN uptake. Up to
now, it is not known how free ODN have access to
w xcell cytoplasm or nucleus 45,46 . Nevertheless, when
free ODN highly concentrated phosphodiester or
.phosphorothioate are endocytosed by cells, most of
the molecules must be trapped inside lysosomes. At
least a small part escapes and reaches the cytosol to
w xallow the antisense effects already described 3,5 .
Similarly, solid carriers such as nanoparticles are
supposed to promote, via endocytosis, the cellular
w xuptake of the associated ODN 47 . Consequently,
any ODN carrier that efficiently drives ODN through
cell membranes and then allows at least part of them
to escape from lysosomal compartments may be per-
w xformant 9 . For SMBV, the ODNrSMBV associa-
tion must allow the release of ODN inside cells, with
minimal degradation by lysosomal enzymes. Our re-
sults show that ODN present in cell cytosol are up to
11 fold concentrated after SMBV incorporation, com-
pared to free ODN. Moreover, the proportion of
intact ODN in the cytosol is significantly higher for
SMBV incorporated ODN than for free ODN. It must
be noted that intact ODN are analyzed but we cannot
distinguish ODN still incorporated into SMBV from
dissociated ODN. The intracellular dissociation of the
SMBVrODN complexes can be rapid or progressive.
It can occur either during the endocytic pathway
 .before the complex is in the lysosomes or only after
escaping lysosomes, once the complex reaches the
cytosol. According to this intracellular dissociation,
we can expect various release kinetics of ODN that
will enhance differently the antisense effects.
Taken together, these results show that ODN in-
corporated into SMBV penetrate cells and cytosol
during the 5 h following the treatment, while being
still partially intact. The interval between two consec-
utive administrations could be as short as 5 to 6 h
and, in any case, should be adjusted experimentally
and according to the target mRNA and target protein
half-lives. At the lowest SMBV concentration we
tested 1 mgrml of SMBV, i.e. around 20 nM of
.ODN for the 10% incorporation rate , the SMBV
incorporated ODN uptake is already increased 3 times
compared to free ODN uptake and their life-time is
prolonged 8 times, in culture growth medium contain-
ing 10% bovine serum. Cytotoxicity results show that
SMBV administrated at this concentration are not
toxic on MCF-7 cells: for a 3- or 6-h incubation,
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more than 80% of cells are viable. Because cationic
liposomes DOTMA, GIBCO or DOTAP,
.Boehringer are usually incubated during 3 to 12 h
w xwith cells 43,44 , we tested the longer 12-h incuba-
tion for SMBV and showed that the 1 mgrml is
always in the range of the non-toxic concentrations.
As a conclusion, SMBV appear as efficient ODN
carriers that greatly increase both ODN protection
and ODN intracellular uptake. Moreover, the ODN
are stably incorporated into SMBV, at least over 2
months in water, predicting optimal storage condi-
tions of the ODNrSMBV complexes. We are cur-
rently testing the efficiency of these carriers for
cellular antisense effect.
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